2026-01-07 - Analysis Report
Okay, here's a comprehensive analysis of Hims & Hers Health Inc. (HIMS) based on the data provided, presented in a clear and structured format.

**0. Report Introduction**

This report analyzes the current state of Hims & Hers Health Inc. (HIMS) stock, comparing its performance against the S&P 500 (VOO) and assessing its financial health, recent news, and analyst sentiment.

**1. Return Rate Comparison & Company Overview**

*   **Company Overview:** Hims & Hers Health Inc. is a multi-specialty telehealth company that connects consumers with licensed healthcare professionals, offering personalized treatments for various conditions.
*   **HIMS Cumulative Return:** 114.24%
*   **VOO Cumulative Return:** 69.64%
*   **Divergence:** 44.6 (Relative Divergence: 31.4)
*   **Analysis:** HIMS has significantly outperformed the S&P 500 with a cumulative return substantially higher than the market benchmark. The divergence of 44.6 suggests a considerable difference in performance. The relative divergence of 31.4 indicates that this divergence is currently positioned in the lower third of its historical range.

**Alpha, Beta Analysis:**

| Year       | CAGR  | MDD   | Alpha | Beta | Cap(B) |
|------------|-------|-------|-------|------|--------|
| 2020-2022  | -19.0% | 67.1% | -17.0% | 0.7  | 1.6    |
| 2021-2023  | -65.0% | 67.1% | -66.0% | 1.6  | 2.1    |
| 2022-2024  | 119.0% | 42.0% | 99.0%  | 1.7  | 5.8    |
| 2023-2025  | 114.0% | 57.5% | 52.0%  | 2.1  | 7.8    |

*   **CAGR:** The Compound Annual Growth Rate shows volatile performance, with negative returns in earlier periods and significant positive growth in recent years.
*   **MDD:** The Maximum Drawdown indicates substantial risk, especially in the early periods.
*   **Alpha:** Consistently positive Alpha, especially in recent periods, shows HIMS outperforming its expected return based on market risk (Beta).
*   **Beta:** Beta values consistently above 1 indicate higher volatility than the market. The increasing Beta suggests the stock's sensitivity to market movements has grown over time.
*   **Market Cap:** The increasing market cap indicates growth and investor confidence over time.

**2. Recent Stock Price Fluctuations**

*   **Current Close:** 33.41
*   **Last Market Price:** 35.46 (previous close: 34.71, change: 2.16)
*   **5-day SMA:** 33.47
*   **20-day SMA:** 36.06
*   **60-day SMA:** 41.59

*   **Analysis:** The stock price closed at 33.41, with the last market price at 35.46. The 5-day SMA is below the 20-day SMA, and both are significantly below the 60-day SMA. This suggests a recent downtrend, with the short-term moving average falling below the longer-term averages. The recent market price increase of 2.16 indicates a slight positive rebound, but the overall trend suggests caution.

**3. Technical Indicators & Expected Return**

*   **Market Risk Indicator (MRI):** 0.8 (Medium Investment)
*   **RSI:** 25.88 (Oversold)
*   **PPO:** -0.33
*   **Hybrid Signal:** Buy 100% with cash (26 shares - Very Safe - MRI:0.90). Monthly invest 1.3% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-12-01)
*   **Recent (20 days) relative divergence change:** -1.7 (Short-term decrease)
*   **Expected Return (%):** 45.6

*   **Analysis:**
    *   The MRI indicates a medium investment recommendation, suggesting a moderate level of risk.
    *   The RSI of 25.88 signals an oversold condition, which *could* indicate a potential buying opportunity. However, it's crucial to consider this in conjunction with other indicators.
    *   The negative PPO indicates the short-term moving average is below the long-term moving average, supporting the downtrend mentioned earlier.
    *   The hybrid signal is a strong buy.
    *   The recent decrease in relative divergence suggests recent underperformance compared to the S&P 500.
    *   The high expected return of 45.6% is attractive, but it is based on long-term projections and may not materialize.

**4. Recent News & Significant Events**

*   **Key Headlines:**
    *   **[2026-01-02] HIMS Stock On A Losing Spree: Here's Why:** Suggests recent negative momentum.
    *   **[2026-01-06] Hims & Hers Health: Could Start To Look Interesting In 2026 (NYSE:HIMS):** Implies potential for future growth or turnaround.
    *   **[2025-12-16] Hims & Hers Health (HIMS): Taking Stock of Valuation After a Sharp 90‑Day Pullback:**  Indicates a valuation reassessment after a price decline.
    *   **[2025-11-17] Hims & Hers Health, Inc. Announces $250 Million Share Repurchase Program Authorization:** A positive sign as it can boost the stock price and signals confidence in the company.
    *   **[2025-12-24] Hims & Hers Health Stock (HIMS) Opinions on Recent Volatility and Expansion:** Highlights recent volatility and growth initiatives.
    *   **[2026-01-06] Hims & Hers Enters 2026 On Solid Ground — Stock Rises Even After Novo Nordisk Leaves It Off Wegovy Partner List:** Shows resilience despite a setback.

*   **Analysis:**  The news headlines present a mixed picture. There are concerns about the recent stock price decline ("Losing Spree," "Sharp Pullback"), but also signs of potential recovery and growth ("Could Start to Look Interesting," "Solid Ground," Share Repurchase Program). The resilience shown after Novo Nordisk's decision is a positive indicator.

**4-2. Analyst Opinions**

*   **Consensus:** Not Provided.
*   **Target Price (avg/high/low):** 44.67 / 85.00 / 25.00
*   **Recent Rating Changes:** Not Provided.

*   **Analysis:** The average target price of $44.67 suggests analysts believe the stock has upside potential from its current price. The wide range between the high ($85.00) and low ($25.00) target prices indicates a significant divergence in analyst opinions and a high degree of uncertainty.

**5. Recent Earnings Analysis**

| 날짜       | EPS  | 매출      |
|------------|------|-----------|
| 2025-11-03 | 0.07 | 0.60 B$   |
| 2025-08-04 | 0.19 | 0.54 B$   |
| 2025-05-05 | 0.22 | 0.59 B$   |
| 2024-11-04 | 0.35 | 0.40 B$   |
| 2025-11-03 | 0.35 | 0.40 B$   |

*   **Analysis:**  Earnings per share (EPS) have been fluctuating, suggesting volatility in profitability. Revenue shows a general uptrend.

**6. Financial Information**

**Revenue and Profitability:**

| Quarter      | Revenue   | Profit Margin |
|--------------|-----------|---------------|
| 2025-09-30   | $0.60B    | 73.80%        |
| 2025-06-30   | $0.54B    | 76.39%        |
| 2025-03-31   | $0.59B    | 73.50%        |
| 2024-12-31   | $0.48B    | 76.81%        |
| 2024-09-30   | $0.40B    | 79.16%        |

**Capital and Profitability:**

| Quarter      | Equity    | ROE       |
|--------------|-----------|-----------|
| 2025-09-30   | $0.58B    | 2.72%     |
| 2025-06-30   | $0.56B    | 7.55%     |
| 2025-03-31   | $0.55B    | 9.01%     |
| 2024-12-31   | $0.48B    | 5.46%     |
| 2024-09-30   | $0.44B    | 17.18%    |

*   **Analysis:** Revenue is growing steadily, indicating increasing sales. Profit margins are relatively high, reflecting good cost management. Equity is growing, demonstrating increasing assets. However, ROE has decreased significantly in the most recent quarter, which could be a cause for concern.

**7. Comprehensive Analysis (Summary)**

Hims & Hers Health Inc. (HIMS) presents a mixed investment profile.

*   **Strengths:**
    *   Significant outperformance compared to the S&P 500 in the past.
    *   Strong revenue growth and high profit margins.
    *   Positive Alpha, indicating outperformance relative to its Beta.
    *   Share repurchase program indicating confidence in the company.
    *   High expected return (although uncertain).

*   **Weaknesses/Risks:**
    *   Recent stock price decline and negative short-term trend.
    *   High Beta, indicating higher volatility than the market.
    *   Fluctuating EPS.
    *   Decreasing ROE in the most recent quarter.
    *   Oversold RSI.

*   **Overall:**
    *   HIMS is a growth stock with considerable potential, but also significant risk.
    *   The recent downtrend and mixed news headlines suggest caution.
    *   The high expected return and analyst target prices indicate potential upside, but this must be balanced against the risks.
    *   Investors should carefully weigh their risk tolerance and investment horizon before investing in HIMS.
    *   Further monitoring of earnings, ROE, and market conditions is recommended.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.